FaceYa FaceYa
Arama Sonuçları
Tüm Sonuçları Gör
  • Katıl
    Giriş yapın
    Başvur
    Site içinde arama yapın
    Theme Switcher
    Night Mode

Site içinde arama yapın

Yeni insanlarla keşfedin, yeni bağlantılar oluşturmak ve yeni arkadaşlar edinmek

  • Web sayfası bildirimcisi
  • EXPLORE
  • Sayfalar
  • Gruplar
  • Events
  • Blogs
  • Offers
  • Jobs
  • Courses
  • Forums
  • Movies
  • Oyunlar
  • Yazı
  • Blogs
  • Kullanıcılar
  • Sayfalar
  • Gruplar
  • Events
  • Wang Judy bir ses eklendi Other
    2026-05-14 06:29:15 -
    GC Biotech’s Role in High-Performance Immune Potentiating Adjuvant Development
    In vaccine development and immunotherapy, one of the most critical challenges is not only delivering an antigen, but ensuring the immune system responds to it in a strong, controlled, and durable way. In many cases, antigens alone are not sufficient to trigger an optimal immune response. This is where immune potentiating adjuvants play a central role. Immune potentiating adjuvants are...
    0 Yorumlar 0 hisse senetleri 666 Views 0 önizleme
    Please log in to like, share and comment!
  • Wang Judy bir ses eklendi Other
    2026-05-28 08:09:27 -
    New Application Scenarios for the AS01 Adjuvant: The ACI-24.060 Alzheimer’s Disease Vaccine Project
    The treatment of Alzheimer’s Disease (AD) has entered the era of "Disease-Modifying Therapies" (DMTs). With the approval of anti-Aβ monoclonal antibodies (such as Lecanemab), the Amyloid Cascade Hypothesis has received clinical validation. However, the safety risks associated with ARIA (Amyloid-Related Imaging Abnormalities) in monoclonal antibody therapies, as well as their high...
    0 Yorumlar 0 hisse senetleri 292 Views 0 önizleme
    Please log in to like, share and comment!
  • Wang Judy bir ses eklendi Other
    2026-06-10 06:59:58 -
    The Potential and Advantages of Using the AS01 Adjuvant in Next-Generation Adjuvanted Influenza Vaccines
    Influenza vaccines represent one of the largest segments of the global vaccine market (with the global market size exceeding $8 billion by 2025). However, the protective efficacy of traditional split-virus vaccines has long hovered between 30% and 50% among individuals aged 65 and older and immunocompromised populations. Additionally, these vaccines require annual updates, offer short-term...
    0 Yorumlar 0 hisse senetleri 6 Views 0 önizleme
    Please log in to like, share and comment!
  • Wang Judy bir ses eklendi Other
    2026-04-10 02:57:04 -
    【Dual Exhibition Tour】GC Biotech's June Roadshow: Veterinary Adjuvant Innovation × Human Vaccine Breakthrough – Dual Tracks Driving the Future of Immunity
    This June, GC Biotech will participate in two major industry exhibitions in China, bringing together the latest innovations in veterinary drugs, vaccine adjuvants, and pharmaceutical technologies. These events provide an important platform for global collaboration, technological exchange, and industry advancement. We sincerely invite partners and industry professionals to visit us, explore new...
    0 Yorumlar 0 hisse senetleri 833 Views 0 önizleme
    Please log in to like, share and comment!
© 2026 FaceYa Turkish
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek 简体中文 日本語 한국어 繁体中文
About Koşullar Gizlilik Contact Us Rehber